Shionogi Company Analysis
Shionogi Company Analysis
$3,000.00
Updated analysis and forecasts based on 2016 company-reported sales.
Pharmavitae Analytics explores Shionogi’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
Updated analysis and forecasts based on 2016 company-reported sales.
Pharmavitae Analytics explores Shionogi’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
Snapshot
- 2021 outlook – Shionogi will add over $300m in revenue out to 2021 as it expands its market share in HIV.
- 2026 outlook – The company will experience minimal growth out to 2026 as mid-term growth is offset by patent expiries.
- Events – The expansion of the HIV franchise and CNS portfolio will offset the continued erosion of Crestor.
Highlights
- Shionogi’s prescription pharmaceutical sales are forecast to achieve modest growth.
- Shionogi’s CNS portfolio will be a major contributor to sales growth.
- New products Tivicay and Triumeq will be the key driver for Shionogi.
Model updates
- Symproic launch in the US and Japan
Analysis structure
Company context
- How is Shionogi strategically poised out to 2026?
- What are Shionogi’s key strengths, weaknesses, opportunities, and threats?
- What are Shionogi’s key catalysts over the next four quarters?
Facts and figures
- What is Shionogi’s forecasted sales performance out to 2026?
- What is the revenue trajectory of Shionogi’s current top 10 products out to 2026?
- Which therapy areas will experience the largest growth and decline?
- What are the portfolio weightings of Shionogi based on the lifecycle of products?
Key therapy areas
- Why will specific therapy areas experience the largest growth and decline?
- What are the detailed competitive dynamics at play in Shionogi’s important therapeutic markets?
- How is Shionogi adapting strategically to internal and external headwinds?
5 EXECUTIVE SUMMARY
6 COMPANY CONTEXT
6 Crestor cliff
6 Shionogi growth strategy
6 Licensing efforts
6 Outlook
6 Shionogi’s SWOT analysis
7 Shionogi’s key events and catalysts
9 FACTS AND FIGURES
9 Shionogi’s prescription pharma sales outlook
9 Shionogi’s therapy area dynamics
13 Shionogi’s top 10 products over 2016–26
16 Shionogi’s launch/core/expiry analysis
18 Shionogi’s financial outlook
19 Shionogi’s M&A history
21 KEY THERAPY AREAS
21 Metabolic
23 Central nervous system
26 Infectious diseases
29 Genitourinary
33 BIBLIOGRAPHY
LIST OF FIGURES
9 Figure 1: Shionogi’s prescription pharmaceutical sales ($m) and growth rate (%), 2013–26
10 Figure 2: Shionogi’s therapy area dynamics, 2016–26
13 Figure 3: Shionogi’s top 10 product sales ($m), 2016–26
16 Figure 4: Shionogi’s launch/core/expiry analysis, 2016–26
18 Figure 5: Shionogi’s operating revenue/cost analysis ($m), 2010–22
LIST OF TABLES
11 Table 1: Shionogi’s sales by therapy area ($m), 2016–26
14 Table 2: Shionogi’s growth drivers and resistors
17 Table 3: Shionogi’s sales by launch, core, and expiry portfolio ($m), 2016–26
19 Table 4: Shionogi’s financial performance, 2015–22
20 Table 5: Shionogi’s key merger and acquisition deals, 2003–16
22 Table 6: Shionogi’s metabolic portfolio ($m), 2016–26
24 Table 7: Shionogi’s central nervous system portfolio ($m), 2016–26
27 Table 8: Shionogi’s infectious diseases portfolio ($m), 2016–26
31 Table 9: Shionogi’s genitourinary portfolio ($m), 2016–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Gene Editing: The Next Breakthrough in Regenerative Medicine 
Sign up to the